Association of apatinib and breast cancer: A systematic review and meta-analysis
Background Breast cancer (BC) is a common malignant tumor. Apatinib in combination with
other treatments has been used for BC; however, its safety and efficacy are not well-known …
other treatments has been used for BC; however, its safety and efficacy are not well-known …
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
K Gaitskell, E Rogozińska, S Platt… - Cochrane Database …, 2023 - cochranelibrary.com
Background Many women, and other females, with epithelial ovarian cancer (EOC) develop
resistance to conventional chemotherapy drugs. Drugs that inhibit angiogenesis …
resistance to conventional chemotherapy drugs. Drugs that inhibit angiogenesis …
Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum‐resistant recurrent ovarian cancer treatment: a retrospective cohort study
A Geng, H Yang, Z Wang, C Wu - Journal of Clinical Pharmacy …, 2022 - Wiley Online Library
Abstract What Is Known and Objective Apatinib, an oral antiangiogenic drug, exerts potential
anti‐tumour effects on platinum‐resistant recurrent ovarian cancer (PROC). This study …
anti‐tumour effects on platinum‐resistant recurrent ovarian cancer (PROC). This study …
[HTML][HTML] miRNA-612 suppresses ovarian cancer cell tumorigenicity by downregulating NOB1
Z Shi, X Zhou, M Bao, R Jia, Y Chu… - American Journal of …, 2022 - ncbi.nlm.nih.gov
MicroRNAs (miRNAs) play crucial roles in cancer progression. Our previous study
demonstrated that NIN1/RPN12 binding protein 1 homolog (NOB1) was a functional …
demonstrated that NIN1/RPN12 binding protein 1 homolog (NOB1) was a functional …